Japan to buy 1.4 mln doses of Daiichi Sankyo COVID vaccine
The purchase is contingent on approval of the shot formulated for the XBB.1.5 Omicron subvariant of the virus. An earlier version of the mRNA-based vaccine was approved in August as a booster, becoming Japan's first home-grown shot for the coronavirus. During the pandemic, Japan mainly relied on imports of mRNA-type vaccines developed by U.S. drugmakers Pfizer and Moderna.
- Country:
- Japan
Japan's health ministry said on Friday it agreed to buy 1.4 million doses of Daiichi Sankyo's updated COVID-19 vaccine. The purchase is contingent on approval of the shot formulated for the XBB.1.5 Omicron subvariant of the virus.
An earlier version of the mRNA-based vaccine was approved in August as a booster, becoming Japan's first home-grown shot for the coronavirus. During the pandemic, Japan mainly relied on imports of mRNA-type vaccines developed by U.S. drugmakers Pfizer and Moderna.
(This story has not been edited by Devdiscourse staff and is auto-generated from a syndicated feed.)
- READ MORE ON:
- Pfizer
- Moderna
- Japan
- U.S.
- Omicron
- health ministry
- Daiichi Sankyo's
- COVID-19
Advertisement
ALSO READ
Frances Tiafoe Triumphs in Epic Showdown Against Ben Shelton at U.S. Open
Thrilling Upsets and Victories Mark Fifth Day at U.S. Open
Coco Gauff Advances to U.S. Open Last 16 in Thrilling Comeback Victory
Successful Western Iraq Raid by U.S. and Iraqi Forces Neutralizes 15 ISIS Operatives
Dramatic Upsets and Thrilling Victories Highlight U.S. Open Day Five